Genome-wide determinants of mortality and motor progression in Parkinson's disease

Authors: Manuela MX TAN, PhD^{1,2,3}, Michael A LAWTON, PhD⁴, Miriam I POLLARD, BSc², Emmeline BROWN, BSc², Raquel REAL, PhD^{2,3}, Alejandro MARTINEZ CARRASCO, MSc^{2,3}, Samir BEKADAR, PhD⁵, Edwin JABBARI, MRCP, PhD^{2,3}, Regina H REYNOLDS, PhD^{6,31}, Hirotaka IWAKI, MD, PhD^{7,8,9}, Cornelis BLAUWENDRAAT, PhD^{7,9}, Sofia KANAVOU, MSc⁴, Leon HUBBARD, PhD¹⁰, Naveed MALEK, MRCP¹¹, Katherine A GROSSET, MD¹¹, Nin BAJAJ, PhD¹², Roger A BARKER, PhD^{13,14,31}, David J BURN, MD¹⁵, Catherine BRESNER, BSc¹⁰, Thomas FOLTYNIE, PhD^{2,3}, Nicholas W WOOD, PhD^{2,3,31}, Caroline H WILLIAMS-GRAY, MRCP, PhD¹³, Ole A ANDREASSEN, MD, PhD^{16,17}, Mathias TOFT, MD, PhD^{1,17}, Alexis ELBAZ, MD, PhD¹⁸, Fanny ARTAUD, PhD¹⁸, Alexis BRICE, MD⁵, Jean-Christophe CORVOL, MD, PhD⁵, Jan AASLY, MD, PhD^{19,20†}, Matthew J FARRER, PhD²¹, Michael A NALLS, PhD^{7,8,9}, Andrew B SINGLETON, PhD^{3,22,23,24,25,26,31}, Michele TM HU, PhD^{27,28,29}, Donald G GROSSET, MD³⁰, Maryam SHOAI, PhD^{22,23,31}, Lasse PIHLSTRØM, MD, PhD¹, Huw R MORRIS, PhD, FRCP^{2,3,31}.

Affiliations

¹ Department of Neurology, Oslo University Hospital, Oslo, Norway

² Department of Clinical and Movement Neurosciences, Queen Square Institute of Neurology, University College London, London, UK

³ UCL Movement Disorders Centre, University College London, London, UK

⁴ Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK

⁵ Sorbonne University, Paris Brain Institute - ICM, Inserm, CNRS, Assistance Publique Hôpitaux de Paris, Departement of Neurology, Hôpital Pitié-Salpêtrière, Paris, France

⁶ Genetics and Genomic Medicine, Great Ormond Street Institute of Child Health, University College London, London, UK

⁷ Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, Maryland, USA

⁸ Data Tecnica International, Washington, DC, USA

⁹ Center for Alzheimer's and Related Dementias, National Institutes of Health, Bethesda, MD, USA

¹⁰ Institute of Psychological Medicine and Clinical Neurosciences, MRC Centre for Neuropsychiatric Genetics and Genomics, Cardiff University, Cardiff, UK

¹¹ Department of Neurology, Institute of Neurological Sciences, Queen Elizabeth University Hospital, Glasgow, UK

¹² Clinical Neurosciences, University of Nottingham, Nottingham, UK

PD Progression GWAS

Tan and colleagues

p2/29

¹³ John Van Geest Centre for Brain Repair, Department of Clinical Neurosciences, University of Cambridge, Cambridge, UK

¹⁴ Wellcome-MRC Cambridge Stem Cell Institute, University of Cambridge, Cambridge, UK
 ¹⁵ Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK

¹⁶ NORMENT, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway

¹⁷ Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway

¹⁸ Paris-Saclay University, UVSQ, Inserm, Gustave Roussy, "Exposome and Heredity" team, CESP, 94807, Villejuif, France

¹⁹ Department of Neurology, St. Olavs Hospital, Trondheim, Norway

²⁰ Department of Neuromedicine and Movement Science (INB), Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology (NTNU), Trondheim, Norway

²¹ Department of Neurology, University of Florida, Gainesville, FL, United States

²² Department of Neurodegenerative Diseases, Queen Square Institute of Neurology, University College London, London, UK

²³ Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK

²⁴ UK Dementia Research Institute, University College London, London, UK

²⁵ National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre, London, UK

²⁶ Institute for Advanced Study, The Hong Kong University of Science and Technology, Hong Kong SAR, China

²⁷ Nuffield Department of Clinical Neurosciences, Division of Clinical Neurology, University of Oxford, Oxford, UK

²⁸ Oxford Parkinson's Disease Centre, University of Oxford, Oxford, UK

²⁹ Department of Clinical Neurology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK

³⁰ School of Neuroscience and Psychology, University of Glasgow, Glasgow, UK

³¹Aligning Science Across Parkinson's (ASAP) Collaborative Research Network, Chevy Chase, MD, 20815.

[†]Deceased

Corresponding authors:

Dr Manuela MX Tan, Department of Neurology, Oslo University Hospital, Oslo, Norway, <u>manuela.tan@medisin.uio.no</u>.

Professor Huw R Morris, Department of Clinical and Movement Neurosciences, UCL Queen Square Institute of Neurology, Royal Free Hospital, Rowland Hill Street, London NW3 2PF, <u>h.morris@ucl.ac.uk</u>.

PD Progression GWAS

Tan and colleagues

p3/29

Running title: PD progression GWAS

Key Words: Parkinson's disease, genetics, progression, genome-wide association study, mortality, survival, clinical milestones

Funding sources: Parkinson's UK, Aligning Science Across Parkinson's through the Michael J Fox Foundation for Parkinson's Research, Southern and Eastern Norway Regional Health Authority

Abbreviations: FUMA = Functional Mapping and Annotation of GWAS; GWAS = Genome-Wide Association Study; H&Y = Hoehn and Yahr; LD = Linkage Disequilibrium; MDS-UPDRS = Movement Disorder Society Unified Parkinson's Disease Rating Scale; PD = Parkinson's Disease; PPMI = Parkinson's Progression Markers Initiative; SNP = Single Nucleotide Polymorphism; SD = Standard Deviation; SE = Standard Error; UKB = UK Biobank.

PD Progression GWAS

Tan and colleagues

p4/29

ABSTRACT

Background: There are 90 genetic risk variants for Parkinson's disease (PD) but currently only five nominated loci for PD progression. The biology of PD progression is likely to be of central importance in defining mechanisms that can be used to develop new treatments.

Methods: We studied 6,766 PD patients, over 15,340 visits with a mean follow-up of between 4.2 and 15.7 years and carried out a genome wide survival study for time to a motor progression endpoint, defined by reaching Hoehn and Yahr stage 3 or greater, and death (mortality).

Findings: There was a robust effect of the *APOE* ε 4 allele on mortality in PD. We identified three novel loci for mortality and motor progression, and nominated genes based on physical proximity and/or expression quantitative trait loci data. One locus within the *TBXAS1* gene encoding thromboxane A synthase 1 was associated with mortality in PD (HR = 2.04 [95% CI 1.63 to 2.56], p-value = 7.71 x 10⁻¹⁰). Another locus near the *SYT10* gene encoding synaptotagmin 10 was associated with mortality just above genome-wide significance (HR=1.36 [95% CI 1.21 to 1.51], p-value=5.31x10⁻⁸). We also report 4 independent loci associated with motor progression: the top locus within *MORN1* (HR=2.76 [95% CI 1.97 to 3.87], p-value=3.1x10⁻⁹), the second most significant locus near *ASNS*, the third most significant locus near *PDE5A*, and a fourth locus within *XPO1*. We have nominated causal genes based on expression quantitative trait loci, colocalization analysis, and tagging of rare variants. Only the non-Gaucher disease causing *GBA1* PD risk variant E326K, of the known PD risk variants, was associated with mortality in PD.

Interpretation: We report six novel loci associated with PD motor progression or mortality. Further work is needed to understand the links between these genomic variants and the underlying disease biology. However, thromboxane synthesis, vesicular peptidergic neurotransmitter release, and phosphodiesterase inhibition may represent new candidates for disease modification in PD.

PD Progression GWAS

Tan and colleagues

p5/29

INTRODUCTION

Parkinson's disease (PD) is a progressive neurodegenerative condition for which there are no treatments to stop or slow disease progression. Large-scale genome-wide case-control association studies (GWASs) of PD have identified 90 independent variants associated with disease risk¹. However, it is also important to study the genetics and biology of disease progression. This will enable the development of potential disease-modifying treatments. There have now been a handful of GWAS which aim to identify genetic variants associated with progression in PD. These have nominated loci in *SLC44A1* (encoding choline transporter like protein -1, involved in membrane synthesis) for progression to Hoehn and Yahr (H&Y) stage 3 or greater,² *APOE* for cognitive progression,³ *LRP1B* (encoding an low-density lipoprotein receptor which is involved in amyloid precursor protein trafficking) for progression to dementia⁴, and *RIMS2* (encoding the RAB3 interacting RIMS2 protein, involved in neurotransmitter release) for progression to PD dementia.⁵ In addition, many candidate gene studies have shown that variants in *GBA1*, *APOE*, and potentially *MAPT*, are associated with the rate of PD motor and cognitive progression.⁶

PD progression may be determined by differential cellular susceptibility, related to mitochondrial function or proteostasis, differential cell to cell spread of pathology, or novel pathways and mechanisms. Risk factors determined from case control studies indicate aetiological pathways and guide future preventive trials, but these may differ from risk factors that determine disease progression. Currently disease modifying treatment trials focus on intervention in recently diagnosed patients, related to disease progression after diagnosis. Work on large scale longitudinal cohorts over the last ten years has now enabled the collaborative study of large clinico-genetic datasets. Here we have carried out two progression GWASs: progression to mortality, and Hoehn and Yahr (H&Y) stage 3 or greater. We have analysed data from 6,766 PD patients with over 15,340 visits and mean follow-up ranging between 4.2 to 15.7 years.

METHODS

We studied 11 cohorts from Europe and America, and included cohorts in each analysis who had sufficient data on the outcomes of interest (see <u>Supplementary Materials</u>). Genotyping, quality control, and imputation was performed in each cohort separately but following the same steps. Only variants with high imputation quality scores (INFO/R2 > 0.8) and minor allele frequency (MAF) > 1% were retained for analysis.

We assessed the following two clinical outcomes: mortality, and H&Y stage 3 or greater. Cohorts were excluded if less than 20 individuals met the outcome of interest during the follow-up period, or < 5% of the total cohort size. Progression to the clinical milestones was

PD Progression GWAS

Tan and colleagues

p6/29

analysed using Cox proportional hazard models. Progression to mortality was assessed from the starting timepoint of PD onset. Progression to Hoehn and Yahr stage 3 or greater was assessed from the time from study entry (baseline visit). Individuals who met the outcome of Hoehn and Yahr stage 3 or greater at study entry were left censored and excluded from analyses. In each model, we adjusted for age at onset, gender, and the first five genetic principal components to adjust for population stratification. Meta-analysis was performed in METAL (version 2011-03-25)⁷, using an inverse variance weighted fixed effects model. GWASs with a genomic inflation factor above 1.2 were excluded from the meta-analysis. Only SNPs that were genotyped in > 1,000 individuals across all cohorts were included in the final results. SNPs with heterogeneous effects across cohorts were also excluded (p-value < 0.05 for Cochran's Q-test for heterogeneity, and/or $l^2 > 80$). The null hypothesis was tested with the standard GWAS significance level of 5 x 10⁻⁸. Results of GWAS uploaded to Functional Mapping and Annotation (FUMA: were https://fuma.ctglab.nl/)⁸ to annotate, prioritise, and visualize GWAS results, and perform gene-set analysis with MAGMA. Genome-wide Complex Trait Analysis conditional and joint analysis (GCTA-COJO, version 1.94.1) was used to identify independently-associated SNPs⁹, using all individuals in the Accelerating Medicines Partnership Parkinson's disease (AMP-PD) whole genome sequencing dataset as a reference sample (N = 9422). Finemapping of the top loci was performed with Probabilistic Annotation INtegraTOR (PAINTOR) (https://bogdan.dgsom.ucla.edu/pages/paintor/) following the recommended pipeline, to prioritize causal variants and integrate functional genomic data^{10–12}. Forest plots for the top SNPs were generated in R v3.6 using the forestplot package, enabling us to determine consistency, and replication of survival risk alleles across cohorts. Further details are provided in the Supplementary Materials.

We also performed candidate variant analysis of the 90 PD risk variants from the most recent PD case-control GWAS,¹ and the cumulative PD genetic risk score (GRS). We also examined associations for other candidate variants that have been reported in PD and Progressive Supranuclear Palsy (PSP) progression: *SLC44A1²*, *RIMS2*, *WWOX*, *TMEM108⁵*, *APOE* ϵ 2 allele, *MAPT* H1 haplotype, and rs2242367 adjacent to the *LRRK2* locus¹³. We analysed the Alzheimer's disease (AD) GRS in relation to PD progression. 38 loci passing genome-wide significance from the latest AD GWAS were used to create the AD GRS.¹⁴ The *APOE* region was excluded from the GRS (hg19/GRCh37 coordinates 19:40,000,000-50,000,000).¹⁴

RESULTS

Overall 6,766 participants with PD were analysed with mean follow-up between 4.2 and 15.7 years (<u>Table 1</u>). We did not have data from regular follow-up visits for all studies as

PD Progression GWAS

Tan and colleagues

p7/29

some studies only contributed mortality data. However, in the studies that had regular follow-up visit data available, over 15,340 visits were analysed (<u>Table 1</u>).

GWAS of mortality

One study was excluded from the meta-analysis of mortality because the study-specific genomic inflation factor was above 1.2 and one study was excluded because less than 20 individuals reached this endpoint (<u>Supplementary Table 1</u>).

5,744 patients were included in the meta-analysis of mortality. Of these, 1,846 (32.1%) individuals had died with a median time to death of 10.6 years from PD onset. 7,696,389 SNPs were present in at least 1,000 individuals and 7,313,918 SNPs passed meta-analysis filtering for heterogeneity and MAF variability. The genomic inflation value of the meta-analysis after filtering was 1.04.



Figure 1. GWAS meta-analysis of mortality. **(A)** The Manhattan plot showing two GWAS significant loci after meta-analysis. The blue dashed line indicates the threshold for genome-wide significance, $p=5x10^{-8}$. SNPs highlighted in red have p-value< $5x10^{-9}$. SNPs highlighted in orange have p-value< $5x10^{-8}$. One nominal association in Chromosome 12 is also annotated with the nearest gene, *SYT10* (p= $5.3x10^{-8}$). **(B)** Forest plot for the top SNP

PD Progression GWAS

Tan and colleagues

p8/29

rs429358 in Chromosome 19, in *APOE*. **(C)** Forest plot for the top SNP rs4726467 in Chromosome 7, in *TBXAS1*. **(D)** Forest plot for the top SNP rs10437796 in Chromosome 12, near *SYT10*. BP = Base Pair, CI = Confidence Interval, HR = Hazard Ratio.

Two loci passed genome-wide significance and were identified to determine mortality in PD (Figure 1). The top SNP was rs429358 in Chromosome 19 ($p=4.0x10^{-10}$), which tags the *APOE* ϵ 4 allele (<u>Table 2</u>). One other locus in Chromosome 7 in *TBXAS1* also reached significance ($p=7.7x10^{-10}$), and another locus in Chromosome 12 near *SYT10* was nominally associated ($p=5.3x10^{-8}$). Regional association plots are shown in Figure 1 and <u>Supplementary Figures 1-3</u>. The top ten independent SNPs identified from GCTA-COJO and their nearest genes are reported in <u>Table 2</u>.

In the MAGMA gene-based test, *APOE* was significantly associated with mortality $(p=1.9x10^{-10})$, and *SYT10* was associated just below genome-wide significance $(p=3.6x10^{-6})$. There was no significant association of any gene-sets or tissues in the MAGMA gene-set analysis and gene property analysis for tissue specificity.

A locus in *TBXAS1* was also significantly associated with PD mortality, with the top SNP rs4726467. This SNP is an expression quantitative trait locus (eQTL), with the effect (minor) allele decreasing expression of *TBXAS1* in blood (eQTLGen; <u>https://www.eqtlgen.org/</u>)¹⁵ but not other tissues as reported in GTEx (<u>https://gtexportal.org/</u>). There was no evidence on GTEx that rs4726467 is a splicing Quantitative Trait Loci (sQTLs). Brain eQTL data at MetaBrain (<u>https://www.metabrain.nl/</u>)¹⁶ did not indicate this SNP was a significant cis-eQTL in any brain regions from European samples.

In LDproxy (<u>https://ldlink.nci.nih.gov/</u>), we identified two coding variants in linkage disequilibrium (LD) within 500kb of the top SNP. One was a synonymous variant in *HIPK2*, rs34093649 (D' = 0.24, R^2 = 0.05, MAF 0.02). There was also one missense variant in *PARP12*, rs2286196, about 89kb away from rs4726467 (D' = 0.34, R^2 = 0.01, MAF = 0.20).

The top SNP in Chromosome 12, rs10437796, is not directly within *SYT10* but increases *SYT10* expression in the testis and decreases expression in the tibial nerve. The SNP also increases expression of the long noncoding RNA (IncRNA) RP11-438D14.2 (ENSG00000259937) in the brain. This is a 'sense intronic' transcript to *SYT10*, a long noncoding transcript which is within an intron of a coding gene and does not overlap any exons. Brain cis-eQTL data from MetaBrain showed that the effect allele A of rs10437796 significantly increased expression of *SYT10* in the cortex but not in other brain regions. This

PD Progression GWAS

Tan and colleagues

p9/29

SNP was not an eQTL or sQTL for any genes in blood in eQTLGen. There were no coding variants in LD with this SNP in LDproxy within a 500kb window.

We also performed colocalization analysis to determine whether the association signals for PD mortality and gene expression are driven by a shared causal variant (see <u>Supplementary Materials</u>; <u>Supplementary Table 2</u>). We used cis-eQTL data from PsychENCODE and eQTLGen to examine gene expression in whole brain or blood, respectively. However, no PD mortality loci showed evidence of colocalization with eQTLs (PP.H4 <0.75). The largest posterior probability was 0.42 for eQTLs regulating CLASRP in brain from the PsychENCODE database (<u>Supplementary Table 2</u>).

We checked the top SNPs and genes (+/- 1 Mb) from the mortality GWAS in the most recent longevity GWAS¹⁷ to see if these were influencing PD-specific or more general mortality and survival. *APOE* and specifically the ε 4 tagging SNP, rs429358, was the strongest signal for longevity (beta = -0.05, p = 9.6x10⁻¹²⁷). The *TBXAS1* SNP, rs4726467, was not associated with longevity (p = 0.82). Other SNPs within or just outside the *TBXAS1* gene boundaries were also not associated with longevity at genome-wide significance. The nearest associated SNP was rs149577943 which lay approximately 1Mb outside of *TBXAS1* (p = 6.1x10⁻⁵). The *SYT10* SNP, rs10437796, was nominally associated with reduced longevity (beta = -0.008, p=0.003) in the longevity GWAS.

GWAS of H&Y stage 3 or greater

3,331 individuals across 5 cohorts were analysed for progression to H&Y stage 3 or greater. 753 individuals (22.6%) met the outcome of H&Y stage 3 or greater, with a median time to H&Y3 of 3.1 years. 6,549,622 SNPs passed filtering for heterogeneity and MAF variability. The genomic inflation factor of the meta-analysis was 1.03. The top ten independent SNPs from GCTA-COJO are reported in <u>Table 3</u>.

Four independent loci were significantly associated with progression to H&Y 3 or greater (p < 5 x 10^{-8}). Regional association plots for all GWAS significant loci are shown in Supplementary Figures 4-7. The top locus was in Chromosome 1, with lead SNP rs115217673 within the *MORN1* gene (Figure 2). The top SNP was not a significant eQTL for any genes, according to GTEx, eQTLGen, or MetaBrain databases. As the *GBA1* gene is also located in Chromosome 1 and is an important factor for PD risk and progression, located 152 Mb away^{18,19}, we checked whether the top SNP rs115217673 was in linkage disequilibrium with any of the common *GBA1* variants (p.E326K, p.N370S, p.T369M, and p.L444P) using the LDpair tool (https://ldlink.nih.gov/?tab=ldpair). However, there was no evidence of linkage disequilibrium between our top H&Y3 locus and any of the main *GBA1* variants (Supplementary Table 3).

PD Progression GWAS

Tan and colleagues

p10/29

Published summary statistics from a previous progression $GWAS^{12}$ were downloaded from <u>https://pdgenetics.shinyapps.io/pdprogmetagwasbrowser/</u> (accessed November 2019). These summary statistics only included variants that passed heterogeneity filters, with MAF > 0.05 and total number of participants > 1000. Our top SNP in *MORN1* was not associated with progression to H&Y3 in the Iwaki summary statistics (beta = 0.61, p = 0.02).

The second most significant locus was in Chromosome 7, with top SNP rs145274312, nearest to the *ASNS* gene. This SNP was also not identified as an eQTL for any genes in the eQTL databases. This SNP was not included in any of the Iwaki summary statistics for H&Y stage, UPDRS2, or UPDRS3.



B rs115217673 (MORN1)

Study	HR	95% CI	
Tracking Parkinson's	2.03	[1.29-3.20]	
Oxford Discovery	4.36	[2.09-9.11]	
PPMI	5.96	[2.34-15.17]	
Oslo	2.19	[0.86-5.56]	
Meta-analysis	2.76	[1.97-3.87]	-
			1.0 2.0 4.0 8.0 Hazard Ratio

C rs145274312 (ASNS)

Study HR 95% CI



D rs113120976 (*PDE5A*)



E rs141421624 (*XPO1*)



PD Progression GWAS

Tan and colleagues

p12/29

Figure 2. GWAS meta-analysis of progression to Hoehn and Yahr stage 3 or greater (H&Y3+). Note that the loci in the Manhattan plot and the forest plots have been labelled with the physically closest genes, though these may not necessarily be the causal genes. (A) The Manhattan plot showing four GWAS significant loci after meta-analysis. The blue dashed line indicates the threshold for genome-wide significance, $p=5x10^{-8}$. SNPs highlighted in red have p-value< $5x10^{-9}$. SNPs highlighted in orange have p-value< $5x10^{-8}$. (B) Forest plot for the top SNP rs115217673 in Chromosome 1, in *MORN1*. (C) Forest plot for the top SNP rs113120976 in Chromosome 7, near *ASNS*. (D) Forest plot for the top SNP rs141421624 in Chromosome 2, in *XPO1*. BP = Base Pair, CI = Confidence Interval, HR = Hazard Ratio.

The third most significant locus was in Chromosome 4, with top SNP rs113120976. This was closest to the protein-coding gene *PDE5A*, however it is also near a long non-coding RNA *LOC107986192* (NR_165235.1). The top SNP is a significant cis-eQTL in blood for *USP53* with the effect allele T decreasing gene expression (eQTLGen). However, the SNP was not an eQTL in other tissues as reported in GTEx and MetaBrain. This SNP was also not included in any of the Iwaki GWAS summary statistics related to motor progression.

Finally, there was a locus in Chromosome 2 which was significantly associated with progression to H&Y3, with top SNP rs141421624. This SNP is intronic in the *XPO1* gene. However, it is also a significant eQTL in blood for the genes *KIAA1841* and *AHSA2* (eQTLGen). It is also a significant eQTL in brain cortex for *C2orf74*, with the effect allele G increasing gene expression (MetaBrain).

In LDproxy (<u>https://analysistools.cancer.gov/LDlink</u>), there were also two missense variants within 500kb in linkage disequilibrium with the lead SNP rs141421624. One of these is rs1729674, a missense variant in *C2orf74*, with a D' of 1.0 and R² of 0.014, and MAF of 0.42. The other variant in LD with the lead SNP is rs76248080, a missense variant in the *CCT4*, D' = 0.55. R² = 0.014, MAF = 0.18. This SNP was also not included in any of the lwaki GWAS summary statistics related to motor progression.

Colocalization analysis did not provide strong evidence for shared causal variants between PD H&Y3 loci and gene expression, with no loci surpassing PP.H4 > 0.75. However, the strongest signal (highest PP.H4) was for the locus in Chromosome 2, which showed some evidence of colocalization with eQTLs for *PUS10* (PP.H4 = 0.69) at the liberal p12 of $1e^{-5}$. p12 is the prior probability that any random SNP in the region is associated with both traits, and though 1e-5 is the default in coloc, it may be too liberal particularly in smaller samples. Full results and figures of colocalization analysis are shown in <u>Supplementary Table 4</u> and

PD Progression GWAS

Tan and colleagues

p13/29

Supplementary Figure 8. There was no strong evidence of colocalization with eQTLs for any of the other PD H&Y3 loci.

Candidate variant analysis

We did not find that any of the 90 PD risk SNPs were associated with PD progression at genome-wide significance (Supplementary Materials; Supplementary Table 5). Two SNPs, representing rare *LRRK2* (rs34637584) and *GBA1* (rs114138760) variants, were not present in our analysis as we filtered out variants with MAF < 1%. Of the 88 PD risk variants tested, we found that only one variant, rs35749011, near *KRTCAP2* and tagging the *GBA1* p.E326K variant, was significantly associated with mortality (p=3.6x10⁻⁴) below the analysis-wide significance threshold (p-value threshold 0.05/88=0.00057). There was also one other variant, rs62333164 in *CLCN3*, which was nominally associated with progression to H&Y3 (p=0.005) (Supplementary Figure 9).

We also examined the association between the PD GRS and progression in each cohort, adjusting for sex, age at onset, and PC1-PC5. The random-effects meta-analysis across cohorts did not show an effect of the GRS on mortality (HR = 0.99 [95% CI 0.95 to 1.04], p = 0.74), or H&Y3+ (HR = 1.02 [95% CI 0.96 to 1.08], p = 0.60).

In the candidate variant analysis, the PSP survival SNP rs2242367 was nominally associated with more rapid progression to mortality in PD (HR=1.13 [95% CI 1.04 to 1.21], p=0.002) (Supplementary Table 6).

Alzheimer's Disease Genetic Risk Score (GRS)

In the random-effects meta-analysis, the AD GRS without *APOE* was nominally associated with mortality (HR=1.06 [95% CI 1.01 to 1.11], p=0.03).

Power calculations

The power to detect a signal in a survival GWAS depends on a number of factors, including effect size, allele frequency of the effect allele, and the proportion of individuals meeting the outcome of interest. Using the 'survSNP' package²⁰, we estimate that this study had 92% power to detect a significant effect ($p < 5x10^{-8}$) for our top *APOE* SNP rs429358 in the mortality GWAS, given an allele frequency of 16%, Hazard Ratio of 1.34, event/death rate of 32.1% and median time to death of 10.6 years. <u>Supplementary Figure 10</u> shows how power changes with different event rates and allele frequencies. Clearly power for progression studies will increase with longer follow-up as more individuals meet the outcomes.

PD Progression GWAS Tan and c

Tan and colleagues

p14/29

DISCUSSION

We have conducted a large meta-analysis GWAS of progression to clinical milestones in PD. We have identified the loci in or near *APOE*, *TBXAS1*, *MORN1*, *ASNS*, *PDE5A*, and *XPO1*, as relevant to survival and motor cognitive progression in PD. The effects were largely consistent and replicated across cohorts, as illustrated in the forest plots and by formal tests of heterogeneity.

APOE: The APOE SNP rs429358 was associated with mortality. APOE is the strongest genetic risk factor for AD,^{14,21} and is also associated with cardiovascular disease (including coronary heart disease / coronary artery disease), and cholesterol levels.²²

In PD, *APOE* has been associated with age at onset,²³ cognition and dementia, and potentially motor progression,²⁴ but not PD risk.^{1,25} In the GWAS of PD age at onset, the effect of *APOE* was shown to be similar between age at onset in cases and age of entry of controls.²³ This suggests that the effect of *APOE* on PD age at onset is more generally related to ageing, and not specific to PD age at onset. Indeed, GWASs of longevity and survival in the general population have identified *APOE* as the strongest genetic factor, with the same $\varepsilon 4$ (rs429358) allele associated with increased mortality²⁶ and found less frequently in long-living individuals.²⁷ Thus, our finding that *APOE* is a risk factor for mortality in PD patients may not be specific to PD.

We also analysed AD GRSs excluding *APOE*. This showed that non-*APOE* AD genetic risk influences mortality in PD, although to a much weaker extent than the *APOE* locus itself.

TBXAS1: *TBXAS1* encodes Thromboxane A Synthase 1, which catalyses the conversion of prostaglandin H2 to thromboxane A2, which acts as a platelet aggregator and vasoconstrictor. Variants in *TBXAS1* have previously been associated with coronary artery disease in a number of GWASs.^{28–31} We showed that a locus in *TBXAS1* was associated with all-cause mortality in PD cohorts. Thus, it is possible that the association between *TBXAS1* and PD mortality may be due to increased coronary artery disease or other non-PD causes.

However, there are a few important factors to consider. Firstly, the locus we identified for mortality in PD cohorts is different from those associated with coronary artery disease, so it may be that different SNPs within this gene have different effects. Secondly, our search of the most recent longevity GWASs¹⁷ suggests that variation at *TBXAS1* does not influence mortality and longevity in the general population. Thirdly, it is also possible that patients with

PD Progression GWAS

Tan and colleagues

p15/29

PD are more susceptible to adverse effects of a SNP than healthy controls, so PD or its treatment increases vulnerability to the SNP effect on coronary artery disease but the cause of death is not able to be classified as 'PD-related'. This has also been seen in previous non-genetic studies of PD mortality.³² Thus future analyses including cause of death are needed to clarify the mechanism through which *TBXAS1* variants influence mortality in PD patients.

SYT10: We also found evidence that a locus near *SYT10* (synaptotagmin 10) in Chromosome 12 was associated with mortality. This protein is a calcium sensor involved in regulation of calcium-dependent exocytosis, specifically related to peptidergic vesicles.³³ Variants in this gene have been linked to heart rate and cardiac cycle phenotypes.^{34–36} This locus was not significantly associated with longevity in the general population, although there was nominal association in the most recent longevity GWAS, (beta=-0.008, p=0.003)¹⁷.

MORN1: This locus in Chromosome 1 affected progression to H&Y3. *MORN1* encodes the MORN repeat containing 1 protein, which contains the Membrane Occupation and Recognition (MORN) repeat. The function of this protein is not very well understood or studied in humans. In the GWAS Catalogue (<u>https://www.ebi.ac.uk/gwas/</u>), SNPs in *MORN1* have been associated with height, coronary artery disease, and mean corpuscular haemoglobin concentration among others.

ASNS: This locus in Chromosome 7 was associated with progression to H&Y3. The top SNP is about 10.5kb away from the gene ASNS encoding Asparagine synthetase. This expressed protein is in the brain. pancreas and stomach (https://www.proteinatlas.org/ENSG00000070669-ASNS). lt converts aspartate and glutamine to asparagine and glutamate,³⁹ with glutamate playing a crucial role as a neurotransmitter. Extracellular glutamate can be neurotoxic primarily through activation of N-methyl-D-aspartate (NMDA) receptors.⁴⁰ This excitotoxicity may contribute to neuronal death in neurodegenerative diseases including PD and AD.^{40,41}

ASNS has been implicated in certain cancers, in particular acute lymphoblastic leukemia, where a lack of ASNS protein expression is targeted with asparaginase therapy. Asparaginase catalyses the hydrolysis of asparagine and glutamine to aspartic acid and glutamate, which causes intracellular asparagine levels to fall and thereby starves the leukaemia cells, leading to cell death and suppressed tumour growth.³⁹ *ASNS* has also been implicated in other cancers, including pancreatic cancer, ovarian cancer, gastric, and hepatic cancers, ^{39,42,43} though some cancers show overexpression of *ASNS*.⁴⁴

PD Progression GWAS

p16/29

Asparaginase had a neuroprotective effect in a cell model of PD, where cells overexpressing SNCA A53T had pathological alpha-synuclein aggregation and increased glutamine levels.⁴⁵ Treatment with asparaginase depleted glutamine and activated the degradation of alpha-synuclein through autophagy and improved mitochondrial function.⁴⁵

XPO1: This locus in Chromosome 2 was associated with progression to H&Y3. The lead SNP is an intronic variant in *XPO1*, however it is also an eQTL for *KIAA1841* and *AHSA2* in blood, and *C2orf74* in brain cortex. In addition, colocalization analysis implicated colocalization with eQTLs for *PUS10*, though there was not strong evidence for a shared causal SNP. In addition, there were two missense variants within 500kb in LD with the lead SNP, in the genes *C2orf74* and *CCT4*.

XPO1 (Exportin 1) transports other proteins from the nucleus to the cytoplasm, specifically proteins containing nuclear export signal (NES), which include tumour suppressors.^{46,47} XPO1 is overexpressed in many cancers, including pancreatic, gastric, prostate, and colorectal cancer, and overexpression is associated with more rapid disease progression and poorer outcomes.^{46,47} Several XPO1 inhibitors are being investigated as therapeutics, including selinexor which has been approved by the US Food and Drug Administration (FDA) for multiple myeloma and diffuse large B-cell lymphoma.⁴⁷

XPO1 also transports anti-inflammatory factors and growth regulating proteins. In PD mouse model, the XPO1 inhibitor eltanexor prevented dopaminergic neuron loss and microglial activation and also rescued locomotor incoordination.⁴⁸

C2orf74, chromosome 2 open reading frame 74, has not been extensively studied. It may be involved in autoimmune disorders, where differences in gene expression have been found in celiac disease,⁴⁹ and GWAS hits within C2orf74 for celiac disease, ulcerative colitis, and Crohn's disease may alter gene expression in thymic tissue.⁵⁰ However, so far it has not been studied in PD.

PDE5A/ USP53: This locus in Chromosome 4 was closest to *PDE5A* but also influenced expression of *USP53*. *PDE5A* encodes Phosphodiasterase 5A, a member of the cyclic nucleotide phosphodiesterase (PDE) family. PDEs are responsible for breaking down the cyclic nucleotides: cyclic adenosine monophosphate (cAMP), and cyclic guanosine monophosphate (cGMP). These are intracellular second messengers involved in many central nervous system processes, such as neurogenesis, apoptosis, and plasticity. Changes in PDE expression and cyclic nucleotide levels may be involved in aging, Alzheimer's disease⁵¹, Huntington's disease, and PD.⁵²

PD Progression GWAS

Tan and colleagues

p17/29

PDE5 specifically breaks down cGMP. Studies have shown that PDE inhibitors like zaprinast restored long-term depression (a form of synaptic plasticity) in mice overexpressing *SNCA* A53T⁵³, and reduced the severity of dyskinesias and increased cAMP and cGMP levels in a hemiparkinsonian rat model.⁵⁴ However *PDE5* is not very highly expressed in the striatum compared to other PDEs and also relative to other tissues, and other PDEs may be important in PD.^{51,52}

The top SNP in this locus was also a significant eQTL for *USP53* in blood. This gene encodes Ubiquitin Specific Peptidase 53, a type of deubiquitinase, which are enzymes that removes ubiquitin from proteins. *USP53* has been linked to hepatocellular carcinoma (a type of liver cancer) and esophageal cancer, where its downregulation was found in tumour tissues from patients.^{55–57} Overexpression of USP53 promoted tumour cell death and reduced tumour growth, suggesting an anti-tumour role in certain cancers.^{56,57}

PD risk variants and candidate variants: In line with previous PD progression GWASs, the majority of the 90 PD risk SNPs were not associated with PD progression.^{2,3,5,58} We showed that one variant, rs35749011, linked to *GBA1* p.E326K (also known as p.E365K) was associated with mortality. Interestingly this variant does not cause Gaucher disease or have a major effect on glucosylceramide levels suggesting a dissociation between glucosylceramide and the role of *GBA1* in PD progression. This is consistent with the recently reported trial data reporting a lack of effect of the glucosylceramide synthase inhibitor venglustat in modifying PD progression.⁵⁹

We were not able to replicate findings for other candidate variants nominated from previous PD progression GWASs. We examined results for rs382940 in *SLC44A1* for progression to H&Y stage 3 or greater,² however this was not associated with progression in any of our results.

We also did not replicate findings for variants in *RIMS2*, *WWOX*, and *TMEM108* which have been reported for PD dementia.⁵ The p-values for these variants were all > 0.3 in our GWASs (<u>Supplementary Table 6</u>), although we did not analyse cognitive impairment or dementia in this study.

We did not find evidence to support *APOE* ϵ 2 and *MAPT* H1 haplotype as factors for mortality. We found some evidence suggesting the PSP mortality SNP, rs2242367,¹³ was also associated with more rapid mortality in PD. This SNP was shown to increase expression of *LRRK2*, possibly through regulation of a long coding RNA, *LINC02555* although there was no colocalisation with *LRRK2*.¹³ This finding could indicate that there is some 'contamination' of PSP cases in our PD cohorts, as PSP can be frequently misdiagnosed as PD and we did not have pathological diagnosis data on the majority of

PD Progression GWAS

Tan and colleagues

p18/29

cases, or alternatively the regulatory effects of this SNP, which is separate from the *LRRK*2 PD risk locus, may influence survival in both PD and PSP.

Limitations: This study is one of the largest GWASs of PD progression and the first largescale GWAS of PD mortality. However larger sample sizes and longer follow-up are needed to detect variants with smaller effects or lower allele frequencies. Secondly, more data is needed on postmortem pathological diagnosis to conduct cause of death analyses, as some of the mortality variants may relate to general population mortality rather than having a specific effect on PD progression. However, *APOE* is the only gene identified in our mortality GWAS that overlaps with general population longevity GWAS. Another limitation is the heterogeneity between cohorts and PD case selection. Our cohorts tend to be recruited from specialist clinics and groups of patients, and this may lead to a tendency to recruit more atypical patients, or rapidly progressing patients. More population-based studies are needed to improve generalisability of these results. Several of our cohorts are also nonincident, with a delay between symptom onset and study entry, and this mean that we are not able to capture the most rapidly progressing patients.

In addition, we nominated genes from the top SNPs based on physical proximity and eQTL databases, however additional fine-mapping and annotation is needed to prioritise causal variants and genes for each locus. Finally, the interpretation of GWAS for neurological disease remains limited by the resolution of the effects of genomic variants on gene expression from bulk RNA sequencing studies. Rapidly increasing sample sizes, and the development of single cell resources will enable a more direct interpretation of the relationship between genomic variants and disease biology.

Conclusions: We conducted two large-scale GWASs of PD progression, including the first GWAS of mortality in PD. We identified six genome-wide significant signals, including *TBXAS1*. We also showed that the genetic factors influencing progression in PD are largely different to those influencing PD risk, emphasising the need for further studies of progression. This work will help us to better understand the biology of PD progression and develop new disease-modifying treatments.

Data availability

GWAS summary statistics are available for download at: <u>https://tinyurl.com/PDprogressionv2</u> (DOI: 10.5281/zenodo.8017385).

All code for our analyses is publicly available at <u>https://github.com/manuelatan/PD-survival-GWAS</u> (DOI: 10.5281/zenodo.7923843).

PD Progression GWAS

Tan and colleagues

p19/29

Tracking Parkinson's data is available through the Tracking Parkinson's portal: https://www.trackingparkinsons.org.uk/about-1/data/. The Oxford Parkinson's Disease Centre Discovery Cohort data (https://doi.org/10.1016/j.parkreldis.2013.09.025) are available on request (Michele Hu, michele.hu@ndcn.ox.ac.uk). The Cambridgeshire Incidence from GP Neurologist Parkinson's to (CamPalGN) (https://www.thebarkerwilliamsgraylab.co.uk/parkinsons-disease/current-studies-pd/) data and the Cambridge clinic data are available on request (Caroline Williams-Gray/ Roger Barker; chm27@cam.ac.uk). Parkinson's Progression Markers Initiative (PPMI) data was accessed from the PPMI platform: https://www.ppmi-info.org/access-dataspecimens/download-data. Queen Square Brain Bank for Neurological Disorders (QSBB) data are available upon request (qsbbmtas@ucl.ac.uk). UK Biobank data were accessed through the UK Biobank: https://www.ukbiobank.ac.uk/enable-your-research/apply-foraccess. Drug Interaction With Genes in Parkinson's Disease (DIGPD) data (https://clinicaltrials.gov/ct2/show/NCT01564992) are available upon request (Jean-Christophe Corvol, jean-christophe.corvol@aphp.fr). Calypso data are available on request to the study team (Huw Morris, h.morris@ucl.ac.uk). The Trondheim Parkinson's Disease Study (Trondheim) data are available on request (https://doi.org/10.14802/jmd.21029). The Oslo Parkinson's Disease data are available on request (Lasse Pihlstrom/ Mathias Toft, lasse.pihlstrom@medisin.uio.no).

Acknowledgements

This research was funded in whole or in part by Aligning Science Across Parkinson's [Grant number: ASAP-000478] through the Michael J. Fox Foundation for Parkinson's Research (MJFF). For the purpose of open access, the author has applied a CC BY public copyright license to all Author Accepted Manuscripts arising from this submission.

This research has been conducted using the UK Biobank Resource under Application Number 46450.

Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative (PPMI) database (https://www.ppmi-info.org/accessdataspecimens/download-data). For up-to-date information on the study, visit <u>www.ppmiinfo.org</u>. PPMI – a public-private partnership – is funded by The Michael J. Fox Foundation for Parkinson's Research and funding partners, including 4D Pharma, AbbVie Inc., AcureX Therapeutics, Allergan, Amathus Therapeutics, Aligning Science Across Parkinson's (ASAP), Avid Radiopharmaceuticals, Bial Biotech, Biogen, BioLegend, BlueRock Therapeutics, Bristol Myers Squibb, Calico Life Sciences LLC, Celgene Corporation, DaCapo Brainscience, Denali Therapeutics, The Edmond J. Safra Foundation, Eli Lilly and

PD Progression GWAS

Tan and colleagues

p20/29

Company, Gain Therapeutics, GE Healthcare, GlaxoSmithKline, Golub Capital, Handl Therapeutics, Insitro, Janssen Pharmaceuticals, Lundbeck, Merck & Co., Inc., Meso Scale Diagnostics, LLC, Neurocrine Biosciences, Pfizer Inc., Piramal Imaging, Prevail Therapeutics, F. Hoffmann-La Roche Ltd and its affiliated company Genentech Inc., Sanofi Genzyme, Servier, Takeda Pharmaceutical Company, Teva Neuroscience, Inc., UCB, Vanqua Bio, Verily Life Sciences, Voyager Therapeutics, Inc., and Yumanity Therapeutics, Inc. (https://www.ppmi-info.org/about-ppmi/who-we-are/study-sponsors).

Declaration of interests

MMXT is employed by Oslo University Hospital. She has received grant support from Parkinson's UK, the Michael J Fox Foundation, and South-Eastern Norway Regional Health Authority (Helse Sør-Øst). MAL received fees for advising on a secondary analysis of an RCT sponsored by North Bristol NHS trust. KG is an independent medical consultant and receives payments from the University of Glasgow. She has no other fees or honoraria to report.J-CC has served on advisory boards for Biogen, Denali, Idorsia, Prevail Therapeutic, Servier, Theranexus, UCB; and received grants from Sanofi and the Michael J Fox Foundation outside of this work. MAN's participation in this project was part of a competitive contract awarded to Data Tecnica International LLC by the National Institutes of Health to support open science research, he also currently serves on the scientific advisory board for Clover Therapeutics and is an advisor to Neuron23 Inc as a data science fellow. OAA is a consultant to HealthLytix. CWG is employed by the University of Cambridge and holds a RCUK/UKRI Research Innovation Fellowship awarded by the Medical Research Council (MR/R007446/1). In the last 36 months, she has received research funding from the Cambridge Centre for Parkinson-Plus, the NIHR Cambridge Biomedical Research Centre, Cure Parkinson's, Parkinson's UK, The Evelyn Trust, and the Michael J Fox Foundation; speaker payments from GSK and World Parkinson's Coalition; and consulting fees from Evidera Inc. RAB has served as an advisor to UCB; BlueRock Therapeutics; Novo Nordisk; Aspen Neuroscience, UCB and Transine Therapeutics. He has received lecture fees from Novo Nordisk. He has received grant support from the MRC, Wellcome, Parkinson's UK, Cure Parkinson's Trust, EU, Novo Nordisk, DRI and ASAP. 'This research was supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215-20014). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care'. He has received royalties from Wiley and Springer-Nature. DGG is an employee of the University of Glasgow. In the past 12 months he reports consultancy fees from the Glasgow Memory Clinic; honoraria for chairing or attending meetings from AbbVie and BIAL Pharma. HRM is employed by UCL. In the last 12 months he reports paid consultancy from Roche and Amylyx; lecture fees/honoraria -BMJ, Kyowa Kirin, Movement Disorders Society. Research Grants from Parkinson's UK, Cure Parkinson's Trust, PSP Association, Medical Research Council, Michael J Fox

PD Progression GWAS

Tan and colleagues

p21/29

Foundation. HRM is a co-applicant on a patent application related to C9ORF72 - Method for diagnosing a neurodegenerative disease (PCT/GB2012/052140).

Ethics

Tracking Parkinson's: West of Scotland Research Ethics Service (WoSRES) Research Ethics Committee gave ethical approval for this study (ref 11/AL/0163). Oxford Discovery: NRES Committee, South Central Oxford A Research Ethics Committee gave ethical approval for this study (ref 16/SC/0108). CamPaIGN: Cambridge Research Ethics Committee gave ethical approval for this study. Cambridge PD Research Clinic: Cambridge Research Ethics Committee gave ethical approval for this study. Cambridge PD Research Clinic: Cambridge Research Ethics Committee gave ethical approval for this study. PPMI: The Research Subjects Review Board at the University of Rochester approved the PPMI study protocol. UK Biobank: UK Biobank has approval from the North West Multi-centre Research Ethics Committee gave ethical approval for this research tissue bank (ref 18/LO/0721). DIGPD: the Ethical committee IIe-De-France VI gave ethical approval for this study (ID project: 2009-A00109-48). Calypso: Wales Research Ethics Committee 3 gave ethical approval for this study. Trondheim: the Ethics Committee of Central Norway gave ethical approval for this study. Torodheim: the Ethics Committee for Medical Research Ethics in South-East Norway gave ethical approval for this study.

PD Progression GWAS

Tan and colleagues

p22/29

References

- 1 Nalls MA, Blauwendraat C, Vallerga CL, *et al.* Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* 2019; **18**: 1091–102.
- 2 Iwaki H, Blauwendraat C, Leonard HL, *et al.* Genomewide association study of Parkinson's disease clinical biomarkers in 12 longitudinal patients' cohorts. *Mov Disord* 2019; : 1–12.
- 3 Tan MMX, Lawton MA, Jabbari E, *et al.* Genome-Wide Association Studies of Cognitive and Motor Progression in Parkinson's Disease. *Mov Disord* 2020. DOI:10.1002/mds.28342.
- 4 Real R, Martinez-carrasco A, Reynolds RH, *et al.* Association between the LRP1B and APOE loci in the development of Parkinson's disease dementia. *Brain* 2022; **awac414**.
- 5 Liu G, Peng J, Liao Z, *et al.* Genome-wide survival study identifies a novel synaptic locus and polygenic score for cognitive progression in Parkinson 's disease. *Nat Genet* 2021. DOI:10.1038/s41588-021-00847-6.
- 6 Fagan ES, Pihlstrøm L. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature. *Eur J Neurol* 2017; **24**: 561-e20.
- 7 Willer CJ, Li Y, Abecasis GR. METAL: Fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010; **26**: 2190–1.
- 8 Watanabe K, Taskesen E, Van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* 2017; **8**: 1–10.
- 9 Yang J, Ferreira T, Morris AP, *et al.* Conditional and joint multiple-SNP analysis of GWAS summary statistics identifies additional variants influencing complex traits. *Nat Genet* 2012; **44**: 369–75.
- 10 Kichaev G, Yang WY, Lindstrom S, *et al.* Integrating Functional Data to Prioritize Causal Variants in Statistical Fine-Mapping Studies. *PLoS Genet* 2014; **10**. DOI:10.1371/journal.pgen.1004722.
- 11 Kichaev G, Pasaniuc B. Leveraging Functional-Annotation Data in Trans-ethnic Fine-Mapping Studies. *Am J Hum Genet* 2015; **97**: 260–71.
- 12 Kichaev G, Roytman M, Johnson R, *et al.* Improved methods for multi-trait fine mapping of pleiotropic risk loci. *Bioinformatics* 2017; **33**: 248–55.
- 13 Jabbari E, Koga S, Valentino RR, *et al.* Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study. *Lancet Neurol* 2021; **20**: 107–16.
- Wightman DP, Jansen IE, Savage JE, et al. A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. Nat Genet 2021;
 53: 1276–82.
- 15 Võsa U, Claringbould A, Westra HJ, *et al.* Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression. *Nat Genet* 2021; **53**: 1300–10.
- 16 Klein N de, Tsai EA, Vochteloo M, *et al.* Brain expression quantitative trait locus and network analysis reveals downstream effects and putative drivers for brain-related diseases. *bioRxiv* 2021; : 2021.03.01.433439.

PD Progression GWAS

Tan and colleagues

p23/29

- 17 Timmers PRHJ, Wilson JF, Joshi PK, Deelen J. Multivariate genomic scan implicates novel loci and haem metabolism in human ageing. *Nat Commun* 2020; **11**: 1–10.
- 18 Parlar SC, Grenn FP, Kim JJ, Baluwendraat C, Gan-Or Z. Classification of GBA1 Variants in Parkinson's Disease: The GBA1-PD Browser. *Mov Disord* 2023; **38**: 489– 95.
- 19 Cilia R, Tunesi S, Marotta G, *et al.* Survival and dementia in GBA -associated Parkinson Disease □: the mutation matters . *Ann Neurol* 2016; **80**: 662–73.
- 20 Owzar K, Li Z, Cox N, Jung SH. Power and Sample Size Calculations for SNP Association Studies With Censored Time-to-Event Outcomes. *Genet Epidemiol* 2012; 36: 538–48.
- 21 Schwartzentruber J, Cooper S, Liu JZ, *et al.* Genome-wide meta-analysis, finemapping and integrative prioritization implicate new Alzheimer's disease risk genes. *Nat Genet* 2021; **53**: 392–402.
- 22 Lahoz C, Schaefer EJ, Cupples LA, *et al.* Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Study. *Atherosclerosis* 2001; **154**: 529–37.
- 23 Blauwendraat C, Heilbron K, Vallerga CL, et al. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and α-synuclein mechanisms. *Mov Disord* 2019; **34**: 866–75.
- 24 Pu JL, Jin CY, Wang ZX, *et al.* Apolipoprotein E Genotype Contributes to Motor Progression in Parkinson's Disease. *Mov Disord* 2021; : 1–6.
- 25 Williams-Gray CH, Goris A, Saiki M, *et al.* Apolipoprotein e genotype as a risk factor for susceptibility to and dementia in Parkinson's Disease. *J Neurol* 2009; **256**: 493–8.
- 26 Rosvall L, Rizzuto D, Wang HX, Winblad B, Graff C, Fratiglioni L. APOE-related mortality: Effect of dementia, cardiovascular disease and gender. *Neurobiol Aging* 2009; **30**: 1545–51.
- 27 Deelen J, Evans DS, Arking DE, *et al.* A meta-analysis of genome-wide association studies identifies multiple longevity genes. *Nat Commun* 2019; **10**. DOI:10.1038/s41467-019-11558-2.
- 28 Van Der Harst P, Verweij N. Identification of 64 novel genetic loci provides an expanded view on the genetic architecture of coronary artery disease. *Circ Res* 2018; 122: 433–43.
- 29 Matsunaga H, Ito K, Akiyama M, *et al.* Transethnic Meta-Analysis of Genome-Wide Association Studies Identifies Three New Loci and Characterizes Population-Specific Differences for Coronary Artery Disease. *Circ Genomic Precis Med* 2020; : 128–38.
- 30 Koyama S, Ito K, Terao C, *et al.* Population-specific and trans-ancestry genome-wide analyses identify distinct and shared genetic risk loci for coronary artery disease. *Nat Genet* 2020; **52**: 1169–77.
- 31 Shadrina AS, Shashkova TI, Torgasheva AA, *et al.* Prioritization of causal genes for coronary artery disease based on cumulative evidence from experimental and in silico studies. *Sci Rep* 2020; **10**: 1–15.
- 32 Ben-Shlomo Y, Marmot MG. Survival and cause of death in a cohort of patients with parkinsonism: Possible clues to aetiology? *J Neurol Neurosurg Psychiatry* 1995; **58**: 293–9.
- 33 Cao P, Maximov A, Südhof TC. Activity-dependent IGF-1 exocytosis is controlled by the Ca 2+-sensor synaptotagmin-10. *Cell* 2011; **145**: 300–11.

PD Progression GWAS

Tan and colleagues

p24/29

- Verweij N, Van De Vegte YJ, Van Der Harst P. Genetic study links components of the autonomous nervous system to heart-rate profile during exercise. *Nat Commun* 2018;
 9: 1–9.
- 35 Verweij N, Benjamins JW, Morley MP, *et al.* The Genetic Makeup of the Electrocardiogram. *Cell Syst* 2020; **11**: 229-238.e5.
- 36 Nolte IM, Munoz ML, Tragante V, *et al.* Genetic loci associated with heart rate variability and their effects on cardiac disease risk. *Nat Commun* 2017; **8**. DOI:10.1038/ncomms15805.
- 37 Zhou J, Liu H, Lin Y, Zhao J. Membrane occupation and recognition nexus (MORN) motif controls protein localization and function. *FEBS Lett* 2022; **596**: 1839–50.
- 38 Xu Z, Gu Y, Chen J, *et al.* Epigenome-wide gene–age interaction study reveals reversed effects of MORN1 DNA methylation on survival between young and elderly oral squamous cell carcinoma patients. *Front Oncol* 2022; **12**: 1–11.
- 39 Lomelino CL, Andring JT, McKenna R, Kilberg MS. Asparagine synthetase: Function, structure, and role in disease. *J Biol Chem* 2017; **292**: 19952–8.
- 40 Granzotto A, Canzoniero LMT, Sensi SL. A Neurotoxic Ménage-à-trois: Glutamate, Calcium, and Zinc in the Excitotoxic Cascade. *Front Mol Neurosci* 2020; **13**: 1–13.
- 41 Mehta A, Prabhakar M, Kumar P, Deshmukh R, Sharma PL. Excitotoxicity: Bridge to various triggers in neurodegenerative disorders. *Eur J Pharmacol* 2013; **698**: 6–18.
- 42 Chiu M, Taurino G, Bianchi MG, Kilberg MS, Bussolati O. Asparagine Synthetase in Cancer: Beyond Acute Lymphoblastic Leukemia. *Front Oncol* 2020; **9**: 1–10.
- 43 Li H, Ning S, Ghandi M, *et al.* The landscape of cancer cell line metabolism. *Nat Med* 2019; **25**: 850–60.
- 44 Gan X, Liu R, Cheng H, Mao W, Feng N, Chen M. ASNS can predict the poor prognosis of clear cell renal cell carcinoma. *Front Oncol* 2022; **12**: 1–14.
- 45 Zhang Q, Gao Y, Zhang J, *et al.* L-Asparaginase Exerts Neuroprotective Effects in an SH-SY5Y-A53T Model of Parkinson's Disease by Regulating Glutamine Metabolism. *Front Mol Neurosci* 2020; **13**: 1–15.
- 46 Xu D, Farmer A, Collett G, Grishin N V., Chook YM. Sequence and structural analyses of nuclear export signals in the NESdb database. *Mol Biol Cell* 2012; **23**: 3677–93.
- 47 Azmi AS, Uddin MH, Mohammad RM. The nuclear export protein XPO1 from biology to targeted therapy. *Nat Rev Clin Oncol* 2021; **18**: 152–69.
- 48 Liu S, Wang S, Gu R, *et al.* The XPO1 Inhibitor KPT-8602 Ameliorates Parkinson's Disease by Inhibiting the NF-κB/NLRP3 Pathway. *Front Pharmacol* 2022; **13**: 1–14.
- 49 Pascual V, Medrano LM, López-Palacios N, *et al.* Different gene expression signatures in children and adults with celiac disease. *PLoS One* 2016; **11**: 1–10.
- 50 Gabrielsen ISM, Amundsen SS, Helgeland H, *et al.* Genetic risk variants for autoimmune diseases that influence gene expression in thymus. *Hum Mol Genet* 2016; **25**: 3117–24.
- 51 Kelly MP. Cyclic nucleotide signaling changes associated with normal aging and agerelated diseases of the brain. *Cell Signal* 2018; **42**: 281–91.
- 52 Erro R, Mencacci NE, Bhatia KP. The Emerging Role of Phosphodiesterases in Movement Disorders. *Mov Disord* 2021; **36**: 2225–43.
- 53 Tozzi A, Costa C, Siliquini S, *et al.* Mechanisms underlying altered striatal synaptic plasticity in old A53T-α synuclein overexpressing mice. *Neurobiol Aging* 2012; **33**:

PD Progression GWAS

Tan and colleagues

p25/29

1792–9.

- 54 Giorgi M, D'Angelo V, Esposito Z, *et al.* Lowered cAMP and cGMP signalling in the brain during levodopa-induced dyskinesias in hemiparkinsonian rats: New aspects in the pathogenetic mechanisms. *Eur J Neurosci* 2008; **28**: 941–50.
- 55 Young MJ, Hsu KC, Lin TE, Chang WC, Hung JJ. The role of ubiquitin-specific peptidases in cancer progression. *J Biomed Sci* 2019; **26**: 1–14.
- 56 Yao Y, Ma W, Guo Y, *et al.* USP53 plays an antitumor role in hepatocellular carcinoma through deubiquitination of cytochrome c. *Oncogenesis* 2022; **11**: 1–12.
- 57 Cheng W, Tang Y, Tong X, *et al.* USP53 activated by H3K27 acetylation regulates cell viability, apoptosis and metabolism in esophageal carcinoma via the AMPK signaling pathway. *Carcinogenesis* 2022; **43**: 349–59.
- 58 Iwaki H, Blauwendraat C, Leonard HL, *et al.* Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. *Neurol Genet* 2019; **5**. DOI:10.1212/NXG.00000000000348.
- 59 Sanofi. Sanofi delivered close to double-digit Q4 2020 business EPS(1) growth at CER. Paris, 2021 https://www.sanofi.com/en/media-room/press-releases/2021/2021-02-05-06-30-00-2170436.

Table 1. Cohort demographics

	Table 1. (Cohort demo	ographics							(which v
Sohort	N PD patients	N male (%)	Age onset, years	Age diagnosis, years	Age entry, years	Disease duration at baseline (time from symptom onset to baseline), years	N observations	Follow-up, years	N who met Hoehn and Yahr 3+ during follow- up, as a fraction of the total number of individuals included for Hoehn and Yahr analysis (%)*	Array not certified by peer rev
racking 'arkinson's	1782	1154 (64.8%)	64.4 (9.8)	66.2 (9.3)	67.5 (9.3)	3.2 (3.0)	7629	4.2 (1.7)	395/1641 (24.1%)	Illumina HumanCore Exome array is with custom content (over 27,000 m custom variants implicated in neurological and psychiatric disorders)
Ixford Iiscovery	842	544 (64.6%)	64.5 (9.6)	66.2 (9.5)	67.4 (9.4)	2.9 (1.8)	3181	4.7 (2.8)	119/731 (16.3%)	Illumina HumanCore Exome-12 v1 or Illumina InfiniumCoreExome-24
PMI	403	263 (65.3%)	59.5 (10.0)	61.0 (9.7)	61.5 (9.7)	2.0 (1.9)	2200	6.0 (1.8)	69/351 (19.7%)	Whole genome sequencing (see https://www.ppmi-info.org/). Only variants passing quality filters (PASS)
ISBB	308	187 (60.7%)	61.8 (10.1)	NA	NA	NA	NA	15.7 (7.7)	NA	Illumina NeuroChip (Illumina Infiniut) HumanCore-24 array with approximately 180,000 custom variants implicated in neurological ed diseases
KB - incident	1174	728 (62.0%)	NA	69.6 (5.5)	64.1 (5.2)	NA	NA	10.1 (2.1)	NA	Affymetrix Applied Biosystems BiLEVE Axium Array and UK Biobank Axium Array
KB - revalent	839	526 (62.7%)	NA	57.4 (7.1)	62.8 (5.5)	5.5 (4.8)	NA	9.8 (2.5)	NA	Affymetrix Applied Biosystems BiLEVE Axium Array and UK Biobank Axium Array
alypso	186	125 (67.2%)	60.0 (10.0)	61.6 (9.8)	67.7 (9.5)	7.7 (5.3)	NA	9.3 (3.9)	NA	Illumina BeadArray Human660-Quad
amPalGN	90	49 (54.4%)	67.9 (10.4)	70.0 (9.7)	70.3 (9.7)	2.5 (2.9)	NA	8.2 (4.3)	NA	االumina BeadArray Human660-Quad
ambridge PD esearch clinic	239	152 (63.6%)	58.6 (12.0)	60.4 (11.4)	65.1 (10.5)	6.8 (6.1)	NA	9.0 (5.0)	NA	해 Illumina BeadArray Human660-Quad : :
IGPD	376	227 (60.4%)	58.7 (10.0)	59.6 (9.9)	62.2 (9.9)	3.5 (1.6)	1940	9.0 (2.1)	76/369 (20.6%)	Illumina Multi-Ethnic Genotyping p Array (MEGA) array
rondheim	192	109 (56.8%)	62.9 (9.7)	NA	NA	NA	390	15.7 (7.1)	NA	Illumina NeuroChip (Illumina Infinium HumanCore-24 array with approximately 180,000 custom variants implicated in neurological diseases)
Islo	335	226 (67.5%)	52.2 (10.2)	54.2 (10.2)	64.0 (9.2)	11.8 (6.3)	NA	9.2 (3.6)	94/239 (39.3%)	Illumina Infinium OmniExpress array

Means (SD) are shown unless otherwise indicated. Data shown are only in individuals who had both clinical and genetic data, after quality control filters have been applied within each cohort. The number of individuals in each cohort with complete data for each outcome of interest (and covariates) may be less than the total number. Follow-up time is calculated as the time from study entry to last visit, death, or last known status date (censoring), whichever is the latest. For QSBB and Trondheim, we did not have data on age at study entry so follow-up is calculated as the time from onset to death.

*Excluding left-censored individuals, i.e. individuals who met Hoehn and Yahr stage 3 or greater at baseline

Abbreviations: CamPaIGN = Cambridgeshire Parkinson's Incidence from GP to Neurologist; DIGPD = Drug Interaction With Genes in Parkinson's Disease; HY3 = Hoehn and Yahr stage 3 or greater; PPMI = Parkinson's Progression Markers Initiative; QSBB = Queen Square Brain Bank pathologically-confirmed PD cases; UKB = UK Biobank

chr	bp	rsID	effect allele	non-effect allele	effect allele freq	nearest gene	distance to gene (BP)	beta	SE	Hazard Ratio	95% CI	p-value	p-value COJO
19	45411941	rs429358	С	Т	0.160	APOE	0	0.295	0.046	1.342	1.23-1.47	1.35E-10	1.60E-10
7	139637422	rs4726467	Т	С	0.021	TBXAS1	0	0.713	0.116	2.039	1.63-2.56	7.71E-10	8.49E-10
12	33635494	rs10437796	А	С	0.098	SYT10	42740	0.304	0.056	1.355	1.21-1.51	5.31E-08	5.76E-08
9	17616880	rs3808753	G	А	0.035	SH3GL2	0	0.448	0.088	1.564	1.32-1.86	3.34E-07	3.52E-07
3	113979619	rs142285045	А	С	0.013	ZNF80	23194	0.836	0.165	2.308	1.67-3.19	3.80E-07	4.06E-07
18	33965217	rs76125680	С	G	0.012	FHOD3	0	0.874	0.174	2.397	1.70-3.37	5.32E-07	5.65E-07
15	34896795	rs35294489	G	A	0.014	GOLGA8B	20959	0.757	0.152	2.131	1.58-2.87	6.07E-07	6.43E-07
5	55533638	rs28811891	Т	С	0.026	ANKRD55	4452	0.544	0.109	1.722	1.39-2.13	6.21E-07	6.49E-07
21	31807104	rs145506557	С	A	0.016	KRTAP13-4	4028	0.896	0.180	2.451	1.72-3.49	6.59E-07	7.27E-07
10	98786658	rs17112311	A	G	0.049	C10orf12	41073	0.364	0.074	1.439	1.25-1.66	8.07E-07	8.31E-07

Table 2. Top 10 independent SNPs from meta-analysis of progression to mortality.

Independent SNPs identified with GCTA-COJO.

Genome coordinates are in build hg19/GRCh37

Abbreviations: BP = base pair, chr = chromosome, CI = Confidence Interval, freq = frequency, GCTA-COJO = Genome-wide Complex Trait Analysis conditional and joint analysis, SE = Standard Error, SNP = Single Nucleotide Polymorphism

Table 3. Top 10 independent SNPs from meta-analysis of progression to Hoehn and Yahr stage 3 or greater

chr	bp	rsID	effect allele	non- effect allele	effect allele freq	nearest gene	distance to gene (BP)	beta	SE	Hazard Ratio	95% CI	p-value	p-value COJO
1	2315032	rs115217673	А	G	0.016	MORN1	0	1.016	0.172	2.762	1.97-3.87	3.09E-09	3.53E-09
7	97470925	rs145274312	А	G	0.011	ASNS	10504	1.872	0.317	6.503	3.49-12.11	3.49E-09	NA*
4	120566153	rs113120976	Т	С	0.013	PDE5A	16172	1.581	0.273	4.859	2.85-8.30	6.95E-09	8.72E-09
2	61742356	rs141421624	G	А	0.017	XPO1	0	0.923	0.167	2.517	1.82-3.49	3.08E-08	3.36E-08
1	231267735	rs74796254	Т	С	0.027	LOC149373	52110	0.693	0.131	2.000	1.55-2.58	1.17E-07	1.27E-07
1	247425485	rs72771919	G	А	0.021	VN1R5	5038	0.770	0.146	2.160	1.62-2.88	1.44E-07	1.55E-07
4	186697549	rs75614365	С	G	0.121	SORBS2	0	0.372	0.071	1.450	1.26-1.67	1.94E-07	2.13E-07
1	43105085	rs75140767	G	А	0.028	PPIH	18621	0.715	0.140	2.044	1.55-2.69	3.26E-07	3.49E-07
2	131557187	rs7566590	А	G	0.042	AMER3	31480	0.573	0.112	1.774	1.42-2.21	3.31E-07	3.58E-07
6	11284774	rs148949229	А	G	0.014	NEDD9	0	1.694	0.334	5.441	2.83-10.46	3.78E-07	4.72E-07
15	82198898	rs58698247	С	Т	0.024	МЕХ3В	135221	0.692	0.136	1.997	1.53-2.61	3.94E-07	4.20E-07

Independent SNPs identified with GCTA-COJO. Genome coordinates are in build hg19/GRCh37

Abbreviations: BP = base pair, chr = chromosome, CI = Confidence Interval, freq = frequency, GCTA-COJO = Genome-wide Complex Trait Analysis conditional and joint analysis, SE = Standard Error, SNP = Single Nucleotide Polymorphism

*One SNP, rs145274312, was not included in the COJO analysis as it was not present in the AMP-PD reference dataset. This is likely because the minor allele frequency is close to 1% in the general population (0.97% in gnomAD non-Finnish European population), however in our PD datasets the allele frequency was >1%



rs429358 (*APOE*) В

Α

Study	HR	95% CI		
Tracking Parkinson's	0.83	[0.56-1.23]		
Oxford Discovery	1.66	[1.20-2.32]		
QSBB	1.40	[1.09-1.79]		
UKB_incident	1.47	[1.23-1.77]		
UKB_prevalent	1.30	[1.05-1.62]		
Calypso	1.80	[1.22-2.67]		
CamPaIGN	1.52	[0.90-2.56]		
DIGPD	1.46	[0.90-2.39]		
Trondheim	1.07	[0.84-1.36]		
Oslo	1.32	[1.02-1.71]		
Meta-analysis	1.34	[1.23-1.47]		-
			0.50	
			0.50	Hazard Ratio

С rs4726467 (*TBXAS1*)

Study	HR	95% CI	
Tracking Parkinson's	2.44	[1.26-4.72]	
Oxford Discovery	2.94	[1.52-5.72]	
QSBB	1.98	[1.21-3.24]	
UKB_incident	1.61	[1.02-2.55]	
UKB_prevalent	2.08	[1.24-3.48]	
Calypso	2.08	[0.79-5.47]	
CamPalGN	6.91	[0.85-56.02]	
DIGPD	1.29	[0.39-4.19]	← ■
Oslo	1.98	[0.77-5.09]	
Meta-analysis	2.04	[1.63-2.56]	
			0.50 1.0 1.5 2.0 2.53.0 4.0 5.06.0

Hazard Ratio

rs10437796 (SYT10) D

Study	HR	95% CI	
Tracking Parkinson's	1.41	[0.98-2.03]	
Oxford Discovery	1.29	[0.86-1.93]	
QSBB	1.11	[0.82-1.51]	
UKB_incident	1.30	[1.03-1.63]	
UKB_prevalent	1.42	[1.09-1.84]	
Calypso	0.73	[0.47-1.15]	<
CamPalGN	1.10	[0.60-2.02]	
DIGPD	1.86	[1.10-3.16]	
Trondheim	1.76	[1.25-2.47]	
Oslo	1.75	[1.26-2.44]	
Meta-analysis	1.36	[1.21-1.51]	-
			0.50 1.0 1.5 2.0 2.5 3.0 3.5 Hazard Patio
			nazalu naliu







C rs145274312 (ASNS)

Study	HR	95% CI	
Oxford Discovery	8.74	[4.38-17.43]	
DIGPD	1.87	[0.45-7.73]	
Meta-analysis	6.50	[3.49-12.11]	
			0.50 1.0 2.0 4.0 8.0 16.0 Hazard Ratio

D rs113120976 (*PDE5A*)



E rs141421624 (*XPO1*)

HR	95% CI						
2.03	[1.26-3.26]			-	-		
2.40	[0.96-6.00]			-	-		
4.75	[2.46-9.17]				-	-	
0.87	[0.21-3.59]			-			
2.69	[1.01-7.19]			_	_		
2.52	[1.82-3.49]				-		
				+			_
	HR 2.03 2.40 4.75 0.87 2.69 2.52	HR 95% Cl 2.03 [1.26-3.26] 2.40 [0.96-6.00] 4.75 [2.46-9.17] 0.87 [0.21-3.59] 2.69 [1.01-7.19] 2.52 [1.82-3.49]	HR 95% CI 2.03 [1.26-3.26] 2.40 [0.96-6.00] 4.75 [2.46-9.17] 0.87 [0.21-3.59] 2.69 [1.01-7.19]	HR 95% CI 2.03 [1.26-3.26] 2.40 [0.96-6.00] 4.75 [2.46-9.17] 0.87 [0.21-3.59] 2.69 [1.01-7.19]	HR 95% CI 2.03 [1.26-3.26] 2.40 [0.96-6.00] 4.75 [2.46-9.17] 0.87 [0.21-3.59] 2.69 [1.01-7.19] 2.52 [1.82-3.49]	HR 95% CI 2.03 [1.26-3.26] 2.40 [0.96-6.00] 4.75 [2.46-9.17] 0.87 [0.21-3.59] 2.69 [1.01-7.19] 2.52 [1.82-3.49]	HR 95% CI 2.03 [1.26-3.26] 2.40 [0.96-6.00] 4.75 [2.46-9.17] 0.87 [0.21-3.59] 2.69 [1.01-7.19] 2.52 [1.82-3.49]

Hazard Ratio